PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) —
Kaskela Law LLC announces that it is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta”) on behalf of the company’s investors.
Since June 2023, shares of Nkarta’s common stock have declined in value from a trading price of over $4.50 per share to a current trading price of approximately $2.00 per share, a cumulative decline of over 55% in value.
The investigation seeks to determine whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in connection with recent corporate actions.
Nkarta stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/nkarta/ , for additional information about this investigation and their legal rights and options.
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.
- Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies - December 5, 2023
- Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology - December 5, 2023
- The Blue Foundation and Blue Federal Credit Union Announce Big Changes - December 5, 2023
